SR2640
SR2640 is a highly efficient and selective LTD4/LTE4 antagonist that can specifically inhibit the smooth muscle contractions induced by LTD4 in the guinea pig ileum and trachea in a concentration-dependent manner, without affecting the contractions caused by histamine. SR2640 can concentration-dependently prevent the binding of 0.4 nM [3H] LTD4 to membrane receptors in guinea pig lung tissue, with an IC50 of 23 nM. SR2640 can shift the dose-response curve for bronchoconstriction induced by intravenous LTD4 in guinea pigs to the right, and the extent of this shift is positively correlated with the dose of SR2640 administered. SR2640 can be used in asthma research[1].
Product Specifications
CAS Number
[105350-26-3]
Product Name Alternative
QMPB
UNSPSC
12352005
Hazard Statement
H315-H319-H335
Target
Leukotriene Receptor
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
O=C(O)C1=CC=CC=C1NC2=CC=CC(OCC3=NC4=CC=CC=C4C=C3)=C2
Molecular Formula
C23H18N2O3
Molecular Weight
370.40
Precautions
P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501
References & Citations
[1]Ian Ahnfelt-Ronne, et al. A novel leukotriene D4/E 4 antagonist, SR2640. European Journal of Pharmacology, 155 (1988) 117-128.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
